Mostrar el registro sencillo del ítem
Embedding Biomimetic Magnetic Nanoparticles Coupled with Peptide AS-48 into PLGA to Treat Intracellular Pathogens
dc.contributor.author | Calogero Gaglio, Salvatore | |
dc.contributor.author | Jabalera Ruz, Ylenia María | |
dc.contributor.author | Montalbán López, Manuel | |
dc.contributor.author | Lázaro Callejón, Marina | |
dc.contributor.author | Maqueda Abreu, Mercedes | |
dc.contributor.author | Carrasco Jiménez, María Paz | |
dc.contributor.author | Laso, Alejandro | |
dc.contributor.author | Iglesias Salto, Guillermo Ramón | |
dc.contributor.author | Jiménez López, Concepción | |
dc.date.accessioned | 2023-01-31T08:44:40Z | |
dc.date.available | 2023-01-31T08:44:40Z | |
dc.date.issued | 2022-12-08 | |
dc.identifier.citation | Gaglio, S.C... [et al.]. Embedding Biomimetic Magnetic Nanoparticles Coupled with Peptide AS-48 into PLGA to Treat Intracellular Pathogens. Pharmaceutics 2022, 14, 2744. [https://doi.org/10.3390/pharmaceutics14122744] | es_ES |
dc.identifier.uri | https://hdl.handle.net/10481/79462 | |
dc.description.abstract | Among the strategies employed to overcome the development of multidrug-resistant bacteria, directed chemotherapy combined with local therapies (e.g., magnetic hyperthermia) has gained great interest. A nano-assembly coupling the antimicrobial peptide AS-48 to biomimetic magnetic nanoparticles (AS-48-BMNPs) was demonstrated to have potent bactericidal effects on both Gram-positive and Gram-negative bacteria when the antimicrobial activity of the peptide was combined with magnetic hyperthermia. Nevertheless, intracellular pathogens remain challenging due to the difficulty of the drug reaching the bacterium. Thus, improving the cellular uptake of the nanocarrier is crucial for the success of the treatment. In the present study, we demonstrate the embedding cellular uptake of the original nano-assembly into THP-1, reducing the toxicity of AS-48 toward healthy THP-1 cells. We optimized the design of PLGA[AS-48-BMNPs] in terms of size, colloidal stability, and hyperthermia activity (either magnetic or photothermal). The stability of the nano-formulation at physiological pH values was evaluated by studying the AS-48 release at this pH value. The influence of pH and hyperthermia on the AS-48 release from the nano-formulation was also studied. These results show a slower AS-48 release from PLGA[AS-48-BMNPs] compared to previous nano-formulations, which could make this new nano-formulation suitable for longer extended treatments of intracellular pathogens. PLGA[AS-48-BMNPs] are internalized in THP-1 cells where AS-48 is liberated slowly, which may be useful to treat diseases and prevent infection caused by intracellular pathogens. The treatment will be more efficient combined with hyperthermia or photothermia. | es_ES |
dc.description.sponsorship | FEDER Operational Program | es_ES |
dc.description.sponsorship | Proyectos de I + D + I, del Plan Andaluz de Investigacion, Desarrollo e Innovacion B-BIO-432-UGR20 B-BIO-268-UGR20 B-CTS-216-UGR20 A-FQM-492-UGR20 | es_ES |
dc.description.sponsorship | Instituto de Salud Carlos III European Commission P20-00346 P20_00339 P20-00233 | es_ES |
dc.description.sponsorship | Spanish Government PI20-01658 | es_ES |
dc.description.sponsorship | Federation of European Microbiological Societies (FEMS) EC2019-005930-P PDC2021-121135.100 FEMS-GO-2020-201 | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | MDPI | es_ES |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | BMNPs | es_ES |
dc.subject | PLGA | es_ES |
dc.subject | AS-48 | es_ES |
dc.subject | Photothermia | es_ES |
dc.subject | Hyperthermia | es_ES |
dc.subject | Magnetic nanoparticles | es_ES |
dc.subject | Antimicrobial peptide | es_ES |
dc.subject | Monocytes | es_ES |
dc.subject | Mycobacterium tuberculosis | es_ES |
dc.title | Embedding Biomimetic Magnetic Nanoparticles Coupled with Peptide AS-48 into PLGA to Treat Intracellular Pathogens | es_ES |
dc.type | journal article | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.identifier.doi | 10.3390/pharmaceutics14122744 | |
dc.type.hasVersion | VoR | es_ES |